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Posttraumatic stress disorder (PTSD) is a debilitating mental condition occurring after 
a tragedy or a traumatic experience, such as rape, assault, natural disasters, war, car or 
plane accidents, etc. PSTD can cause a number of symptoms, such as fear, high anxiety, 
hyperarousal, bad dreams, night mares, etc., existing for a long time after the traumatic event. 
Within recent years, the spread of PTSD has been increased in the whole world, especially 
in Asia (Middle East), particularly among soldiers who have taken part in military conflicts. 
This situation confirms the importance of understanding the way of PTSD development 
and of the improvement of its treatment. This paper is a review of the literature related 
to the respective topics. Like other anxiety disorders, PTSD is related to disruption of the 
endocrine system, particularly disintegration of the hypothalamus-pituitary-adrenal axis 
(HPAA). People suffering from PTSD are characterized by elevated levels of corticotropin-
releasing hormone, low basal cortisol levels, and enhanced negative feedback suppression 
of the HPAA. At present, certain plant-derived compounds are considered a new important 
source to treat PTSD. For example, remedies obtained from saffron are such possible means. 
According to our findings, saffron components may considerably affect some parts of the 
HPAA for reduction of stress-induced corticosterone release. 
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INTRODUCTION
Posttraumatic stress disorder (PTSD) is manifested 
as an aggregation of symptoms following exposure to 
extreme psychologically stressful or severe physically 
damaging events. This exposure can be visual or aural, 
and it can affect people who have been subjected to 
panic and desperation but avoided physical damage. 
Different events may lead to PTSD, such as car or 
plane accidents, criminal events, exposure to physical 
or sexual assaults [1], surviving from a disaster (e.g., 
flood or explosion) [2], or being the witness of the death 
of someone. In fact, all hard and horrifying events that 
can threaten life and safety, or events causing panic of 
not being secured, or repeated incidents are capable of 
inducing this disorder. In some people, the respective 
emotional reactions continue for a long time, and this 
is the line by which healthy individuals and individuals 
having the risk of PTSD are separated.
In these individuals having bad memories related 
to a painful incident, unpleasant feeling of returning 
to the event can be brought to the mind by an 
occasional flux. Due to this reason, individuals with 
PTSD try to avoid all places or people who can 
remind the accidents; even talking about it would 
be avoided. These people have a sense of separation 
from the real world and do not show any interests 
towards the important activities within the social 
environment; they are nervous and irritable. A number 
of psychological and medical treatments have been 
proposed for patients with PTSD. In this review, we 
focused on the history of PTSD, on diagnosis of this 
disorder, and on its treatment. Special attention is paid 
to plant-derived remedies for the treatment of PTSD.
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HISTORY
In 1980, a term “PTSD” for the first time appeared 
in the system of classification of mental disorders. 
This does not mean that the above medical term was 
related to discovery of a new disease. As early as in 
2000 BC, ancient Egyptians were aware of psychologi- 
cal symptoms of post-war mental shifts. Also, ancient 
Greeks observed and described a disturbance similar 
to PTSD among soldiers after the battle of Marathon in 
year 450 BC [3]. In 1975, with the end of the Vietnam 
War, the symptoms of fear, panic, and constant high 
anxiety among American soldiers, who survived the 
battle and returned to their homes, were frequently 
observed. Recently, more than 30 years after the 
Vietnam War, a study conducted on the veterans of 
this war showed that long-term posttraumatic stress 
causes not only a mental suffering; it creates a serious 
risk of physical illnesses and quick death. Statistical 
examinations showed that 7-8% of the general 
population suffered from PTSD symptoms during 
their period of life [4–6]. In Iran medical records, it 
has been demonstrated that more than 80% of war 
veterans are more or less prone to PTSD symptoms [7]. 
Common mental health problems have been reported 
among people who were often at the frontline of the 
battle [8]. 
RECOGNITION
Clinical features of PTSD are the most painful 
feelings that the incidents may happen again, and 
the problems may exist for months and even years 
although the event will not occur again. On physical 
examinations, the patients often feel guilty, rejected, 
and humiliated; sometimes perceptual errors and 
illusions are observed. In cognitive testing, the patients 
may demonstrate impaired memory and attention, and 
these phenomena could mostly be attributed to the 
increase in the adrenalin level. As is generally known, 
this hormone is produced be adrenals under stress 
conditions, and its release provides physical fitness 
for a rapid response in the case of danger; when stress 
is removed, this index should fall. In PTSD, memory 
recalls of the incident raise the adrenalin level, which 
can cause secondary stress, restlessness, and insomnia 
[9]. 
The hippocampus is a part of the CNS mostly 
responsible for processing memories. High levels 
of the hormones (adrenalin in particular) released 
during stress may disturb normal functioning of the 
hippocampus. This means that memories of traumatic 
events and nightmares will be continued and cannot 
be processed correctly. If the stress is removed, and 
the adrenalin level returns to the norm, the brain will 
be able to repair the damage; bad memories will be 
processed and adequately recognized, and nightmares 
and other symptoms will be lost. Posttraumatic 
disorders typically associated with changes induced by 
intense acute or chronic stress are frequently placed in 
the group of anxiety disorders as a mental illness [10]. 
PTSD, like other anxiety disorders, occurs, to a 
significant extent, as a result of dysfunction of the 
neuroendocrine mechanisms and endocrine system. 
That mostly “followed the disintegration of the 
hypothalamo-pituitary axis and adrenals per se” [1, 
11, 12]. According to endocrinological studies, three 
common features have been reported in patients 
suffering from PTSD. These are: (i) reduction in 
the plasma cortisol level, (ii) increase in the level 
of corticotropin-releasing hormone (CRH) in the 
cerebrospinal fluid (CSF) and plasma, and (iii) 
increased inhibition of the hypophyseal (pituitary)-
adrenal system (HAS) through a negative feedback. 
Therefore, the clinical pattern of PTSD is a paradox 
from the endocrinilogical point of view because 
increased activity of the hypothalamo-pituitary-
adrenal axis (HPAA) is a central component associated 
with stress. At the same time, an insufficient level of 
pituitary-adrenal (HAS) activity should be considered 
a crucial shift in the regulatory endocrinological 
influences observed in PTSD patients. 
The mechanism of the emergence of this disease 
has not been studied adequately. It is known, however, 
that patients with anxiety disorders demonstrate 
either low or normal cortisol levels in the blood [13, 
14], high CRH levels in the CSF and plasma [15, 
16], as well as enhanced inhibition of the pituitary-
adrenocortical system realized via negative feedback 
[12, 17]. High CRH combined with high vasopressin 
in neurosecretory cells and nerve terminals in the 
hypothalamus is created under stress condition, and 
this intensifies the synthesis and secretion of ACTH 
from the pituitary, as well as those of a releasing 
hormone, corticoliberin [18, 19]. 
In terms of the prognosis, it is noteworthy that 
the PTSD symptoms may significantly fluctuate 
over time. The severity of symptoms is the greatest 
during periods of high stress; about 30% of patients 
completely recover, while about 10% demonstrate 
no improvement of worsening of the symptoms. 
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Generally, according to DSM4, when the disease is 
diagnosed until 4 weeks after the event and continues 
from 2 days to 4 weeks, it is called a reparable 
disorder. However, when acute psychiatric and 
remaining symptoms are observed during more than 
4 weeks, PTSD is diagnosed with certainty. Generally, 
when a person has been exposed to a stressful event 
and regularly recalls this incident in mind during 
more than one month, he/she may show the following 
symptoms: (i) restlessness and agitation, aggressive 
behavior, feelings of alienation from others; (ii) 
isolation and difficulties in interpersonal relationship; 
(iii) guilt and shame, careless and emotional poverty 
that makes them stay away from the others; (iv) a 
developmental regression procedure, return to basic 
behaviors of a child (e.g., thumb sucking, etc.); (v) 
excessive emotional and behavioral arousal (constant 
state of alert); (vi) sleep disturbances, nightmares, and 
scary dreams (frightening dreams without a specific 
content); (vii) avoidance of thoughts and feelings, 
avoidance of places that remind unpleasant events; 
(viii) repeated memories on the traumatizing events; 
(ix) repeated games related to the traumatic experience 
(in children), and (x) interference with daily work, 
difficulties in concentration and learning [20, 21].
PATHOGENESIS OF PTSD
Neuroanatomy. At present, three areas in the brain 
have been identified, which may change during 
PTSD; these are the prefrontal cortex, amygdalar 
complex, and hippocampus. Many respective studies 
have been carried out on patients of the Vietnam War. 
For example, observations of soldiers with injured 
heads revealed that the prefrontal cortex plays an 
important role in the prevention or development of 
PTSD symptoms. In human studies, the amygdale 
has shown to be strongly involved in the formation 
of emotional memories, especially fear-related ones. 
Neuroimaging studies in humans revealed both 
morphological and functional aspects of changes in 
the above cerebral structures related to PTSD [22]. 
It was found that the hippocampus, i.e., the structure 
specifically associated with the ability to place 
memories within the correct spatial/temporal context 
and with the ability to recall memories, is suppressed 
during intense stress [23]. Koenen et al. [9] showed 
that the state of the hippocampus exerts a strong 
influence on PTSD. Veterans of the Vietnam War with 
PTSD showed a 20% reduction in the volume of their 
hippocampus compared with the veterans who did not 
suffer from such symptoms. Therefore, it is thought 
that inhibition of the hippocampal functions related to 
partial degeneration of hippocampal neuronal circuits 
during severe stress determines obsessive reminding 
of the incident occurred in patients with PTSD [12, 
24]. As was mentioned, persistent fear in patients 
with PTSD could be due to impairments of the HPAA, 
noradrenergic system of the locus coeruleus, and 
connections between the limbic system and frontal 
cortex. The HPAA is a coordinator of the hormonal 
response under stress conditions. If the event is 
traumatic, the HPAA is stimulated, and activation of 
the noradrenergic locus coeruleus system consequently 
leads to a physiologically excessive increase in the 
strength of memory consolidation on the event. Thus, 
PTSD patients regularly remind the time and place of 
the event bleak picture. 
It seems that the noradrenergic locus coeruleus 
system plays an important role in increasing the 
power of memory consolidation due to stress. Studies 
on animal models have shown that neuropeptide Y 
reduces the secretion of norepinephrine (noradrenalin), 
and this plays an important role in reducing the anxiety 
level in patients with PTSD. Human studies showed 
that concentrations on neuropeptide Y are reduced in 
patients suffering from this disorder [25].
Roles of Hormones in Creating PTSD. PTSD 
symptoms appear when stress causes a severe 
increase in the secretion of adrenalin (epinephrine) 
in circulation. High concentration of adrenalin causes 
significant neurochemical and neurophysiological 
changes in the brain. These shifts may remain for a 
long time and maintain a sense of fear in the person. 
High levels of stress hormones suppress the functions 
of the hypothalamus, and this is an important factor in 
the occurrence of PTSD symptoms. This disorder can 
cause a series of considerable biochemical changes 
in the brain and in the entire body, which differ 
from those in other psychological disorders, such as 
different types of depression. The responses of patients 
with PTSD to the dexamethasone test are much more 
intense than those in patients with a depression 
disorder. In addition, patients with such dexamethasone 
test pattern often demonstrate lower concentrations of 
cortisol and higher concentrations of catecholamines 
in their urine than other depressed patients. Also, 
the norepinephrine/cortisol ratio in patients with 
PTSD is much higher than that in “usual” depressed 
patients. These changes occurring in subjects with 
PTSD significantly differ from those observed under 
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conditions of the fight-or-flight response in people 
faced the stress, where concentrations of both cortisol 
and catecholamines increase in a parallel manner. 
Patients with PTSD demonstrate increased levels of 
CRH and cerebral catecholamines, which is indicative 
of a considerable disorder of the HPAA function. This 
axis is responsible for coordination of the hormonal 
responses to stress. It seems that, due to the increased 
sensitivity of glucocorticoid receptors in patients with 
PTSD, impairment of the HPAA and negative feedback 
inhibition results in a reduced cortisol concentration. 
Thus, because of increased sensitivity of the HPAA 
in patients with PTSD. Non-adaptive learning paths 
can be formed due to the increase of fear. Thus, it is 
likely that the levels of cortisol should be precisely 
considered to be a significant factor leading to 
symptoms of PTSD. It was found that war veterans 
having lower concentrations of cortisol in their saliva 
than other soldiers with normal cortisol levels were 
more susceptible to PTSD. Because cortisol plays 
an important role in the general maintenance of 
homeostasis, disorders in the latter during stress in 
patients with PTSD may lead to persistent feelings of 
fear in them. Other studies have shown that serotonin 
levels are relatively low (frequently abnormally) in 
PTSD patients. As is known, the serotonergic system is 
involved in the formation of mood, anxiety, aggression, 
and irritability; it also provides stabilization of the 
secretion of glucocorticoids [26, 27].
Similarly to CRH, vasopressin plays a role in 
the stress responses and acts synergistically with 
the above releasing hormone [28, 29]. Both above 
hormones are produced in neurosecretory cells of 
the hypothalamus and exert strengthening effects 
on the synthesis and secretion of ACTH from the 
pituitary and release of the latter hormone in stressful 
situations [18, 19]. CRH produced by neurons in the 
paraventricular nucleus (PVN) of the hypothalamus is 
involved in neuroendocrine control of ACTH secretion 
from the pituitary anterior lobe. Also, CRH enhances 
the activity of the sympathetic nervous system. 
Increases in the release of vasopressin and CRF start 
an endocrine response to the stressful situation and 
ultimately stimulate the release of proopiomelano- 
cortin (POMC), ACTH, and beta-endorphin. ACTH is 
a key moderator of glucocorticoid secretion from the 
adrenal cortex. Glucocorticoids, particularly cortisol 
in humans and corticosterone in rats, act as the main 
effect of HPAA activation in the control of body 
homeostasis in response to stress. As it was reported, 
patients with PTSD, due to high baseline levels of CRH 
in the CSF and plasma, react to intravenous injections 
of CRH by slow secretory ACTH responses from the 
pituitary. Because of the continued presence of high 
concentrations of anterior pituitary CRH, receptors 
of the latter undergo desensitization, and the above-
mentioned responses are reduced [30-32]. According 
to the results of the dexamethasone suppression test, 
another treatment has been proposed within recent 
years. This test is used to measure dexamethasone-
induced inhibition of the HPAA [30]. 
It should be noted that there are conflicting opin- 
ions in neurobiology of PTSD. For example, some 
studies have shown that there is no clear relationship 
between the blood cortisol levels and PTSD symptoms. 
At the same time, most studies of the major causes 
of PTSD symptoms demonstrated that increased 
concentrations of CRH, decreases blood cortisol 
levels, and increased negative feedback suppres- 
sion of the HPAA are the main correlates of this 
mental disorder.
APPROACHES TO PTSD TREATMENT
Psychological Techniques. Based on the above-
mentioned data and considering the aim of improving 
mental and physical health of the patients, researchers 
focused their attention on both physical and 
psychological aspects of the disease and proposed 
psychological and physical therapy for PTSD 
treatment. In particular, the National Institute for 
Health and Care Excellence (NICE) suggested trauma-
focused psychological therapy (Cognitive Behavioral 
Therapy, CBT) or an Eye Movement Desensitization 
Reprocessing (EDMR) technique before specific 
medication can be used. 
Two psychotherapeutic approaches for treating 
PTSD patients have been proposed; these approaches 
are based on different general concepts, cognitive 
psychology and behaviorism. Behavioral interventions 
may include learning of how effectively confront fears 
and avoid places or people that could remind stress-
inducing events. The use of sedation techniques and 
accepting the feelings of the patient are effective in 
reducing the symptoms of posttraumatic stress. 
A crisis intervention technique is based on attempts 
to restore normal mental functions of the patients. 
Psychiatrists are focused on the methods allowing 
patients to solve problems related to coping skills and 
to create a supportive environment for the patient. 
It was also found expedient to form a support group 
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for people who are experiencing stress symptoms. 
Members of these groups of patients receive the 
emotional support from others who have experienced 
similar symptoms and conditions; they also learn 
coping skills and how to manage the conditions. 
All these treatments must be led and performed by 
a specialist having the sufficient experience in the 
treatment of PTSD. These meetings should be carried 
out by an expert during at least 8 to 12 weeks; each 
session takes 60 to 90 min [33]. 
Cognitive behavioral therapy (CBT) is another 
treatment method that helps patients to think 
differently about bad memories. Therefore, the 
subjects become less stress-affected and more 
manageable.  Usually,  this  treatment includes 
multiple sessions (with relaxation) that help pati- 
ents “to feel pleasant to think about unpleasant events.” 
An eye movement desensitization and reprocessing 
(EMDR) technique uses recording of eye movements 
to help the brain to process unpleasant incidents. This 
technique seems somewhat strange, but the respective 
treatment was found to be rather effective. 
Psychological therapies are usually ineffective if 
PTSD symptoms continue for more than a month. In 
other cases, impaired functions, such as inadequate 
performance of the patient’s job, etc, need transition 
toward drug treatments. Although PTSD should 
be considered an independent risk form for health, 
combined bad habits can threaten the patient’s health. 
For example, 45% of people with PTSD are smokers; 
some of these patients, when trying to escape from 
emotional problems, tend to use alcohol and drugs 
[34]. 
Treatment of PTSD with Natural Herbal 
Products. Effects of medical plants and their 
derivatives in the treatment of various diseases are 
studied more and more extensively within recent years. 
These studies have shown that a number of medicinal 
herbs demonstrate comparable (or even greater) 
efficiency in the respective cases than “traditional,” 
“standard” pharmacological agents. At the same time, 
there are very few studies of applications of medicinal 
plants for the treatment of PTSD. We concentrated our 
attention to such a plant as saffron and shall try to 
describe the respective results in more detail. 
Saffron, Crocus sativus L. (Iridaceae) is a plant 
known from ancient times, which has been used during 
centuries as a food ingredient (spice). It is also known 
in folk medicine as an antispasmodic, expectorant, and 
even as aphrodisiac. Saffron has a bitter taste mostly 
due to the presence of a component called picrocrocin. 
This compound can be converted by thermal 
decomposition or fermentation to aromatic aldehydes, 
saffronil, in particular. Saffron components, such as 
crocin, are glycosides consisting of a carotenoid called 
crocitin (which is responsible for the color of saffron) 
and sugar. The main physiologically active ingredients 
of saffron are safronal, crocin, and crocetin [35, 36]. 
Saffron has been demonstrated to be rather highly 
efficient with respect to neurological abnormalities. 
For example, saffron was effective in reducing 
symptoms of depression and anxiety. These effects in 
humans were comparable with those of imipramine 
and fluoxetine. The effects of the saffron extract were 
checked out on experiments on mice and demonstrated 
a high efficiency in reducing the anxiety level [37]. 
An inhibitory effect of this herb in reducing symptoms 
of anxiety and dependence of morphine in the 
conditioned place preference test were shown [38]. 
Previous studies demonstrated that the saffron extract 
and its active components (safronal) improve brain 
functions (through inhibition of serotonin reuptake and 
stimulation of GABA receptors) in some pathologies, 
such as Alzheimer disease, epilepsy, and other seizure 
disorders in humans [39]. Sahraei et al. [40] described 
positive effects of the aqueous saffron extract and 
safronal, which improved mental and physical 
symptoms of stress and those related to PTSD. The 
effects were clearly dose-dependent. In this study, the 
animals, 21 days after termination of a stress-induced 
disorder, were exposed to environmental stress for the 
second time. Groups that received the saffron extract 
or safronal did not show significant disorders, while 
the control groups demonstrated strong hormonal 
effects and also strong anorexia. It could be supposed 
that saffron derivatives influence the inner core of 
the amygdale (basolateral nuclei). At the same time, 
the saffron extract and safronal exerted no effects on 
behaviors associated with the dopaminergic system, 
such as exploratory movements. Finally, it was 
concluded that, on the one hand, a positive effect of 
the extract (moderation of stress-related symptoms) 
was clearly present. On the other hand, the efficacy of 
the saffron extract with respect to the basal ganglia of 
the amygdale was lacking. It should be supposed that 
the respective compounds of the aqueous extract of 
saffron probably reduced corticosteron secretion and 
inhibited anorexia. Thus, the effects on the adrenal 
cortex and hypothalamus should be considered [40, 
41]. The saffron extract may realize some of its effects 
by blocking glutamate receptors and by increasing 
concentrations of glutamate and dopamine in the 
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rat brain. These neurotransmitters are involved in 
facilitation of memory-related cerebral phenomena 
and facilitation of release of the hormones from the 
hypothalamus. It seems that the release of these two 
neurotransmitters is altered under stress conditions 
in line with the release of corticosterone and memory 
reinforcement [42, 43]. In another study, Halataei et 
al. [44] showed that the saffron aqueous extract much 
stronger affected metabolic responses in electric 
shock-induced stress (release of corticosteroids, 
anorexia, and weight loss in animals) than the ethanol 
extract of saffron did. This effect is mediated by the 
amygdalar complex [45] and hypothalamus [46]. 
It was shown that there is a close overlap between 
the effects of stress and addictive drugs [47-49]; this 
was demonstrated on animal models. Moffet et al. in 
2006 [50] highlighted stress phenomena induced by 
maternal separation in young rats; it was shown that 
this situation intensifies self-administration of cocaine. 
On the other hand, it was shown in human studies 
that prenatal stress tends to cause high probabilities 
of smoking, using of marihuana, consumption of 
alcohol, and using amphetamines in adulthood [51]. 
In another study, Sahraei et al. [40] showed the 
ability of saffron to provide inhibitory effects on 
the mesocorticolimbic system. So, saffron helps to 
improve the state of people suffering from defective 
functioning of this system. At the same time, this mean 
(or a group of means) does not have side effects of 
addictive drugs. Thus, consumption of saffron-based 
means is prospective with respect to the reduction of 
physiological symptoms of stress in people involved 
in a stressful job and other stress-inducing situations 
[40].
CONCLUSIONS
The above-described data demonstrate the importance 
of adequate functioning of the HPAA and the state 
of the respective neuroendocrine and hormonal 
systems under stress and post-stress conditions. Thus, 
compounds capable of normalizing the control of 
production of the hormones secreted by the above 
axis, such as corticosterone and cortisol, are likely 
to have the ability to reduce PTSD symptoms. Today, 
great attention is paid to the use of “non-chemical” 
treatments, such as herb-based means, to cure the 
above-described pathologies. It is obvious that further 
studies are urgently necessary to understand the 
mechanisms of plant-derived agents and their possible 
role in modifying the control in multiple-organ 
systems. Saffron is an example of the plants that could 
be effectively applied in the treatment of PTSD and 
disorders close to the latter. The compounds contained 
in this plant can help to normalize regulation of 
corticosterone release and the state of the respective 
central neuronal mechanisms, which allow one to 
reduce PTSD symptoms in the respective patient 
contingent with minimum induction of side effects. 
This paper is a review of the published data, and 
confirmation of its correspondence to the ethical norms 
for experiments on animals and/or studies of humans is no 
necessary.
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ПОСТТРАВМАТИЧНИЙ СТРЕС-РОЗЛАД (ПТСР): 
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Р е з ю м е
Посттравматичний стрес-розлад (ПТСР) є психіатричною 
патологією, що розвивається після трагічної або травмати-
зуючої події – смерті/убивства, згвалтування, природних ка-
тастроф, воєнних дій, автомобільних або авіаційних аварій. 
ПТСР може бути пов’язаний з багатьма симптомами – жа-
хом, сильною тривогою, надмірним збудженням, негативни-
ми думками, нічними кошмарами, прояви котрих тривають 
протягом значного часу після травматизуючої події. Впро-
довж останніх років розповсюдження випадків ПТСР у сві-
ті, особливо на Середньому Сході та в Азії, збільшилося, зо-
крема серед солдатів, що брали участь у воєнних діях. Така 
ситуація підкреслює важливість розуміння того, як розвива-
ється ПТСР, та розробки підходів до його лікування. Наша 
стаття є оглядом даних літератури щодо відповідного кола 
питань. Як і інші розлади, пов’язані з тривожністю, ПТСР 
значною мірою базується на дисфункції ендокринної систе-
ми, зокрема на дезінтеграції гіпоталамо-гіпофізарно-адре-
налової осі (ГГАО). Для людей із ПТСР є характерними ви-
сокі рівні кортикотропін-рілізінг-гормону, низькі базальні 
рівні кортизолу та посилена супресія функції ГГАО на осно-
ві негативного зворотного зв’язку. В наш час певні препара-
ти рослинного походження розглядаються як важливі засоби 
для лікування ПТСР. Зокрема, такими ліками можуть бути 
препарати, отримані із шапрану. Згідно з нашими даними, 
речовини, що містяться в шапрані, взаємодіють із деякими 
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POSTTRAUMATIC STRESS DISORDER (PTSD)
ГГАО та забезпечують зменшення вивільнення кортикосте-
рону, індукованого стресом. 
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